Simultaneous estimation of some antiretroviral drugs from tablets by reverse phase high performance liquid chromatography method

Indian Drugs

Volumn 42, Issue 10, 2005, Pages 681-684

  Pai, N R ^a   Desai, A S ^a  

^a D G RUPAREL COLLEGE   (India)

Author keywords

Abacavir; Lamivudine; Zidovudine. RP HPLC

Indexed keywords

EID: 70249135963     PISSN: 0019462X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Indian Pharmacopoeia, Addendum, The controller of publications, New Delhi, 2002, Page No. 889.
2. INDIAN PHARMACOPOEIA, ADDENDUM, THE CONTROLLER OF PUBLICATIONS, NEW DELHI, 2002, PAGE NO. 913.
3. THE UNITED STATE PHARMACOPOEIA, FIRST SUPPLEMENT TO USP 26-NF 21, APRIL 2003, PAGE NO. 1055.
4. INDIAN PHARMACOPOEIA, ADDENDUM, THE CONTROLLER OF PUBLICATIONS, NEW DELHI, 2002, PAGE NO. 936.
5. BRITISH PHARMACOPOEIA, VOL. II, HER MAJESTY'S STATIONARY OFFICE, LONDON, 2003, 1963.
6. EUROPEAN PHARMA, 4TH EDITION, PAGE NO. 2163.
7. THE UNITED STATE PHARMACOPOEIA, FIRST SUPPLEMENT TO USP 26-NF 21, APRIL 2003, 1950.
8. MERCK INDEX, 13TH EDITION (MONOGRAPH 5367, 6514, 10177) PAGE NO. 889, 958, 1809.
9. PEREIRA A. S. KENNEY, SIMULTANEOUS DETERMINATION OF LAMIVUDINE AND ZIDOVUDINE CONCENTRATION IN HUMAN PLASMA USING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY. J Chromato Gr B Biomed Sci Appl 2001 FEB 25; 751(2): 371-6
10. GULICK R. M., MELLORES J. W. HAVLIR D ET AL. TREATMENT WITH ZIDOVUDINE AND LAMIVUDINE IN ADULTS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION AND PRIOR ANTIRETROVIRAL THERAPY. New Eng J Med 1997; 337; 734-9.
11. AYMARD G., LEGRAND M., TRICHEREAU N. ET AL. DETERMINATION OF TWELVE ANTIRETROVIRAL AGENTS IN HUMAN PLASMA SAMPLE USING REVERSED PHASE HPLC. J Chromato Group B 2000; 744:227-40.
12. VERNE A. SIMON, MAMADOU D. THIAM, LEVIN C. LIPFORD DETERMINATION OF SERUM LEVELS OF THIRTEEN HUMAN IMMUNODEFICIENCY VIRUS SUPPRESSING DRUGS BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY. DEPT OF HEALTH, STATE OF FLORIDA. 1217 PEARL STREET, JACKSONVILLE, FL 32202, USA.
13. A RANDOMIZED TRIAL OF METABOLIC AND BODY COMPOSITION CHANGES IN PATIENTS SWITCHING FROM PI-CONTAINING REGIMENS TO ABACAVIR (ABC). C. FISAC, E. FUMERO, M. CRESPO, B. ROSÛN, N. VIRGILI, E. RIBERA, E. FERRER, J. M. GATELL, AND D. PODZAMCZER. HOSP. BELLVITGE, HOSP. VALL D'HEBRON, HOSP. CLIN., BARCELONA, SPAIN.
14. SWITCHING PROTEASE INHIBITORS TO ABACAVIR (ABA): A RANDOMIZED, MULTICENTER, OPEN-LABEL, SIMPLIFICATION TRIAL, E. MARTINEZ, D. PODZAMCZER.
15. A RANDOMISED, CONTROLLED, OPEN-LABEL STUDY OF REVISION OF ANTIRETROVIRAL REGIMENS CONTAINING STAVUDINE (D4T) AND/OR A PROTEASE INHIBITOR (PI) TO ZIDOVUDINE (ZDV)/LAMIVUDINE (3TC)/ABACAVIR (ABC) TO PREVENT OR REVERSE LIPOATROPHY: 48-WEEK DATA. M. JOHN, I. JAMES, E. MCKINNON, D. NOLAN, S. HERRMANN, A. CAIN, O. P. MARTINEZ, A. WHITE AND S. MALLAL. ROYAL PERTH HOSP. AND MURDOCH UNIV., PERTH, AUSTRALIA AND GLAXOSMITHKLINE, GREENFORD, UK.
16. IMPROVEMENTS IN LIPOATROPHY (LA) ARE OBSERVED AFTER 24 WEEKS WHEN STAVUDINE (D4T) IS REPLACED BY EITHER ABACAVIR (ABC) OR ZIDOVUDINE (ZDV). G. MCCOMSEY, T. LONERGAN, R. FISHER, M. SENSION, C. HOPPEL, V. WILLIAMS, L. ROSS, AND J. HERNANDEZ CASE WESTERN RESERVE, CLEVELAND, OH; UNIV. OF CALIFORNIA, SAN DIEGO; GLAXOSMITHKLINE, RES. TRIANGLE PARK, NC; NORTH BROWARD HOSP. DISTRICT, FT. LAUDERDALE, FL; AND LOUIS STOKES VA MED. CTR., CLEVELAND, OH.